CSL Ltd

CSL

Company Profile

  • Business description

    CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

  • Contact

    655 Elizabeth Street
    MelbourneVIC3000
    AUS

    T: +61 393891911

    E: [email protected]

    https://www.csl.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    29,904

CSL Ltd News & Analysis

investing

Podcast: Investing Compass

Morningstar Australia's podcast series.
stocks

ASX healthcare leader sees further cuts to fair value

Fiercer competition expected to squeeze margins.
stocks

Top stocks of the year: Which opportunities remain in 2026?

A deep dive into the most traded stocks by Aussies in 2025 - and what this signals for the year ahead.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,642.2020.90-0.24%
CAC 407,807.87162.01-2.03%
DAX 4022,839.56662.69-2.82%
Dow JONES (US)46,021.43203.72-0.44%
FTSE 10010,063.50241.79-2.35%
HKSE25,338.97161.61-0.63%
NASDAQ22,090.6961.73-0.28%
Nikkei 22553,372.531,866.87-3.38%
NZX 50 Index12,946.03105.58-0.81%
S&P 5006,606.4918.21-0.27%
S&P/ASX 2008,448.8023.50-0.28%
SSE Composite Index4,013.166.610.16%

Market Movers